How to Perform FISH in Cholangiocarcinoma
FISH for cholangiocarcinoma is performed on biliary brush cytology specimens obtained during ERCP, using multi-probe sets (most commonly UroVysion or optimized pancreatobiliary probes) to detect polysomy (gain of ≥2 chromosomes) in at least 5 cells, with the test requiring separate validation for each tissue type according to ACMG technical standards 1.
Specimen Collection and Preparation
The primary specimen for FISH in cholangiocarcinoma is biliary brush cytology obtained during endoscopic retrograde cholangiopancreatography (ERCP) 2, 3, 4. Transpapillary forceps biopsy specimens can also be used 5. The key advantage of brush specimens is that they are often the only available tissue from the tumor.
Separate validations are mandatory when using FISH on different tissue types—conventional cytogenetic preparations require different validation than paraffin-embedded tissues 1. This is critical because FISH test effectiveness varies significantly with tissue type.
Probe Selection and Validation
Standard Probe Sets
Two main probe approaches are used:
1. UroVysion Probe Set (most commonly used):
- Contains centromere enumeration probes for chromosomes 3,7, and 17
- Originally designed for bladder cancer but adapted for cholangiocarcinoma
- Sensitivity: 30.8-55.1% in cholangiocarcinoma 5, 3
- Specificity: 90.8-100% 5, 3
2. Optimized Pancreatobiliary FISH Probes (superior performance):
- Probes targeting 1q21, 7p12, 8q24, and 9p21
- Sensitivity: 64.7% (significantly higher than UroVysion's 45.9%, p<0.001)
- Specificity: 92.9% 4
- This represents the most recent high-quality evidence for probe selection
Extended Probe Systems
For comprehensive genetic profiling, a 4-probe system targeting 7q31, 11q13 (CCND1), 17p13 (TP53), and 9p21 (INK4 locus) with respective centromeric probes can detect hyperdiploidy plus structural aberrations like deletions and amplifications 2.
Technical Validation Requirements
Probe Localization (Mandatory First Step)
Score a minimum of 5 metaphase cells to verify each probe hybridizes to appropriate chromosome targets and no other chromosomes 1. Use male subject cells when possible to exclude Y chromosome cross-hybridization 1.
Three acceptable methods for probe localization:
- Concurrent DAPI banding
- Sequential G-/R-/Q-banding
- Known abnormal sample (preferred for break-apart/fusion probes) 1
Probe Sensitivity and Specificity
Establish by analyzing at least 40 chromosomes targeted by the probe:
- For autosomal targets: score 20 metaphase cells
- For sex chromosome targets: score 40 metaphase cells 1
Optimization Parameters
Empirically establish optimal conditions for:
- Reagent and probe concentrations
- Denaturation temperature and timing
- Hybridization temperature and timing
- Slide washing parameters 1
These factors critically affect signal intensity and nonspecific fluorescence.
Interpretation Criteria
Positive FISH Results
Polysomy definition: At least 5 cells exhibiting gain of ≥2 chromosomes (for chromosomes 3,7, or 17 with UroVysion) 5, 3, 6.
Alternative criterion: More than 10 trisomic cells for chromosomes 3 or 7 6.
Critical caveat: Isolated chromosome 7 trisomy can yield false negatives 6. A malignancy diagnosis should only be made with a polysomic pattern, not isolated trisomy.
Quantitative vs. Qualitative Testing
For cholangiocarcinoma, FISH is quantitative testing because abnormalities may be present in only some cells (not every cell) 1. This is particularly important for neoplasia-associated abnormalities where multiple alternative signal patterns exist 1.
Clinical Performance and Limitations
Diagnostic Accuracy
When combined with conventional cytology:
- FISH increases sensitivity from 53.8-69.4% to 69.2-77.6% 3, 6
- Maintains high specificity (82.4-100%) 3, 6
- FISH is particularly valuable for cytologically negative or atypical cases 3, 6
Special Population: Primary Sclerosing Cholangitis (PSC)
Major limitation: FISH performance is significantly reduced in PSC patients. In PSC surveillance:
- Positive FISH in PSC with CCA: only 11% (1/9 specimens)
- False positives in PSC without CCA: 2% (2/94 specimens) 7
- Specificity remains 100% for differentiating CCA from IgG4-related sclerosing cholangitis 5
The clinical utility of FISH for CCA surveillance in PSC patients is questionable based on the most recent 2025 evidence 7.
Forceps Biopsy Specimens
When using transpapillary forceps biopsies:
- Sensitivity: 55.1%
- Specificity: 100%
- Complementary use with H&E increases sensitivity from 69.4% to 77.6% without reducing specificity 5
Practical Implementation Algorithm
- Obtain biliary brush cytology during ERCP (or forceps biopsy if needed)
- Perform conventional cytology first
- If cytology is negative, atypical, or suspicious: proceed with FISH
- Use optimized pancreatobiliary probes (1q21, 7p12, 8q24, 9p21) if available, otherwise UroVysion
- Score until 5 cells with polysomy (≥2 chromosome gains) are identified
- Interpret cautiously in PSC patients due to reduced sensitivity and potential false positives
- Require polysomic pattern (not isolated trisomy) for malignancy diagnosis
Critical Pitfalls to Avoid
- Do not use FDA-approved probes off-label: Any deviation from manufacturer instructions invalidates FDA approval and requires full laboratory validation 1
- Do not diagnose malignancy based on isolated chromosome 7 trisomy: This can be a false negative pattern 6
- Do not rely solely on FISH in PSC patients: Recent evidence questions its utility in this population 7
- Do not skip tissue-specific validation: Separate validations are mandatory for different specimen types 1
- Do not use probes without confirming absence of cross-hybridization: Probes with significant cross-hybridization should not be used 1